Anti-lipoapoptotic effect of Artemisia capillaris extract on free fatty acids-induced HepG2 cells

BMC Complementary and Alternative Medicine

Volumn 14, Issue , 2014, Pages

  Jang, Eungyeong ^a   Shin, Min Hee ^a   Kim, Ki Suk ^a   Kim, Yoomi ^a,b   Na, Yun Cheol ^b   Woo, Hong Jung ^a   Kim, Youngchul ^a   Lee, Jang Hoon ^a   Jang, Hyeung Jin ^a  

^a Kyung Hee University   (South Korea)

^b Korea Basic Science Institute (KBSI)   (South Korea)

Author keywords

Artemisia capillaris (AC); C Jun NH2 terminal kinase (JNK); HepG2; Lipoapoptosis; Non alcoholic steatohepatitis (NASH); P53 up regulated mediator of apoptosis (PUMA)

Indexed keywords

ARTEMISIA CAPILLARIS EXTRACT; CASPASE 3; CASPASE 9; FATTY ACID; OIL; OLEIC ACID; PALMITIC ACID; PROTEIN BAX; PROTEIN BCL 2; PUMA PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ANTILIPOAPOPTOTIC ACTIVITY; ARTEMISIA CAPILLARIS; ARTICLE; CELL VIABILITY; CELL VIABILITY ASSAY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; FATTY LIVER; HEPATOBLASTOMA CELL LINE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPOLIPEMIA; LIPID STORAGE; MTT ASSAY; NONALCOHOLIC FATTY LIVER; STAINING; STEATOSIS;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ARTEMISIA; CASPASES; CELL SURVIVAL; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; HEP G2 CELLS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPID METABOLISM; MODELS, BIOLOGICAL; PLANT EXTRACTS; PROTO-ONCOGENE PROTEINS;

EID: 84904528469     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-14-253     Document Type: Article

References (46)

1. Snel M, Jonker JT, Schoones J, Lamb H, Roos A, Pijl H, Smit JWA, Meinders AE, Jazet IM. Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int J Endocrinol 2012, 2012:18.
2. Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 2013, 98(2):483-495.
3. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40(6):1387-1395.
4. Lavine JE, Schwimmer JB. Nonalcoholic fatty liver disease in the pediatric population. Clin Liver Dis 2004, 8(3):549-558. viii-ix.
5. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 2006, 290(5):G852-858.
6. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43(2 Suppl 1):S99-s112.
7. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011, 141(4):1249-1253.
8. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011, 46(Suppl 1):63-69.
9. Durazzo M, Belci P, Collo A, Grisoglio E, Bo S. Focus on therapeutic strategies of nonalcoholic fatty liver disease. Int J Hepatol 2012, 2012:9.
10. Leamy AK, Egnatchik RA, Young JD. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res 2013, 52(1):165-174.
11. Malhi H, Barreyro FJ, Isomoto H, Bronk SF, Gores GJ. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut 2007, 56(8):1124-1131.
12. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125(2):437-443.
13. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006, 44(1):27-33.
14. Malhi H, Bronk SF, Werneburg NW, Gores GJ. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem 2006, 281(17):12093-12101.
15. Cha JD, Jeong MR, Jeong SI, Moon SE, Kim JY, Kil BS, Song YH. Chemical composition and antimicrobial activity of the essential oils of Artemisia scoparia and A. capillaris. Planta Med 2005, 71(2):186-190.
16. Son CG, Choi WJ, Shin JW, Han SH, Cho JH, Song KC, Cho CK. Effects of gamichunggantang on hyperlipidemia. Acta Pharmacol Sin 2003, 24(2):133-139.
17. Pan J, Liu G, Liu H, Qiu Z, Chen L. Effects of artemisia capillaris on blood glucose and lipid in mice. Zhong Yao Cai 1998, 21(8):408-411.
18. J-y Y, J-h L. Effects of Saenggantanggami-bang on Nonalcoholic Fatty Liver Disease Model Induced by Fatty Acids. Korean J Orientint Med 2010, 31(2):331-345.
19. Hong JH, Hwang EY, Kim HJ, Jeong YJ, Lee IS. Artemisia capillaris inhibits lipid accumulation in 3 T3-L1 adipocytes and obesity in C57BL/6 J mice fed a high fat diet. J Med Food 2009, 12(4):736-745.
20. Wang JH, Choi MK, Shin JW, Hwang SY, Son CG. Antifibrotic effects of Artemisia capillaris and Artemisia iwayomogi in a carbon tetrachloride-induced chronic hepatic fibrosis animal model. J Ethnopharmacol 2012, 140(1):179-185.
21. Hong J-H, Lee J-W, Park J-H, Lee I-S. Antioxidative and cytoprotective effects of Artemisia capillaris fractions. BioFactors 2007, 31(1):43-53.
22. Jang SI, Kim YJ, Lee WY, Kwak KC, Baek SH, Kwak GB, Yun YG, Kwon TO, Chung HT, Chai KY. Scoparone from Artemisia capillaris inhibits the release of inflammatory mediators in RAW 264.7 cells upon stimulation cells by interferon-gamma Plus LPS. Arch Pharm Res 2005, 28(2):203-208.
23. Lee SG, Jeong HJ, Lee EJ, Kim J, Choi SW. Antioxidant and Anti-inflammatory Activities of Ethanol Extracts from Medicinal Herb Mixtures. Korean J Food SCI Technol 2011, 43(2):200-205.
24. Liu JF, Ma Y, Wang Y, Du ZY, Shen JK, Peng HL. Reduction of lipid accumulation in HepG2 cells by luteolin is associated with activation of AMPK and mitigation of oxidative stress. Phytother Res 2011, 25(4):588-596.
25. Ricchi M, Odoardi MR, Carulli L, Anzivino C, Ballestri S, Pinetti A, Fantoni LI, Marra F, Bertolotti M, Banni S, Lonardo A, Carulli N, Loria P. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol 2009, 24(5):830-840.
26. Cazanave SC, Elmi NA, Akazawa Y, Bronk SF, Mott JL, Gores GJ. CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. Am J Physiol Gastrointest Liver Physiol 2010, 299(1):G236-243.
27. Cazanave SC, Mott JL, Elmi NA, Bronk SF, Werneburg NW, Akazawa Y, Kahraman A, Garrison SP, Zambetti GP, Charlton MR, Gores GJ. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem 2009, 284(39):26591-26602.
28. Tolman KG, Dalpiaz AS. Treatment of non-alcoholic fatty liver disease. Ther Clin Risk Manag 2007, 3(6):1153-1163.
29. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008, 9(3):231-241.
30. Nakano K, Vousden KH. PUMA, a Novel Proapoptotic Gene, Is Induced by p53. Mol Cell 2001, 7(3):683-694.
31. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28(4):360-369.
32. Unger RH, Orci L. Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 2002, 1585(2-3):202-212.
33. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007, 46(4):1081-1090.
34. Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS, Mukherjee P, Friedman SL, Eng FJ. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005, 54(1):142-151.
35. Chavez-Tapia NC, Rosso N, Tiribelli C. In vitro models for the study of non-alcoholic fatty liver disease. Curr Med Chem 2011, 18(7):1079-1084.
36. De Gottardi A, Vinciguerra M, Sgroi A, Moukil M, Ravier-DallAntonia F, Pazienza V, Pugnale P, Foti M, Hadengue A. Microarray analyses and molecular profiling of steatosis induction in immortalized human hepatocytes. Lab Invest 2007, 87(8):792-806.
37. Yamashita R, Saito T, Satoh S, Aoki K, Kaburagi Y, Sekihara H. Effects of dehydroepiandrosterone on gluconeogenic enzymes and glucose uptake in human hepatoma cell line, HepG2. Endocr J 2005, 52(6):727-733.
38. Yao HR, Liu J, Plumeri D, Cao YB, He T, Lin L, Li Y, Jiang YY, Li J, Shang J. Lipotoxicity in HepG2 cells triggered by free fatty acids. Am J Transl Res 2011, 3(3):284-291.
39. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, Poniachik J. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004, 106(6):635-643.
40. Kakisaka K, Cazanave SC, Fingas CD, Guicciardi ME, Bronk SF, Werneburg NW, Mott JL, Gores GJ. Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis. Am J Physiol Gastrointest Liver Physiol 2012, 302(1):G77-84.
41. Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM, Sanyal AJ. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008, 134(2):568-576.
42. Singh R, Wang Y, Xiang Y, Tanaka KE, Gaarde WA, Czaja MJ. Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology 2009, 49(1):87-96.
43. Gottlieb E, Haffner R, King A, Asher G, Gruss P, Lonai P, Oren M. Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis. Embo j 1997, 16(6):1381-1390.
44. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001, 7(3):673-682.
45. Armstrong MJ, Houlihan DD, Rowe IA. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 363(12):1185. author reply 1186.
46. Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, Modi A, Nagabhyru P, Sumner AE, Liang TJ, Hoofnagle JH. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2009, 29(2):172-182.